
Three pharma stocks where FIIs raised stake in the March quarter
Subscribe to enjoy similar stories.Indian pharma stocks are attracting foreign institutional investors (FIIs) due to their strong export orientation, especially in regulated markets like the US, and consistent demand for generics and speciality drugs.Companies are benefiting from cost advantages, improving compliance records, and a growing focus on complex formulations and APIs.Additionally, defensive characteristics during global uncertainty make pharma appealing. Here are three pharma stocks where FIIs have hiked their stake in the March 2026 quarter.Shilpa Medicare is a niche Indian pharma company focused on oncology APIs, complex formulations, and CDMO services.
It is transitioning toward higher-margin segments, such as biologics and speciality drugs.FIIs slightly increased their holding from 10.97% to 11.08% in the March 2026 quarter. This indicates mild buying interest and a positive bias.
It suggests gradual accumulation rather than aggressive investment and should be assessed alongside earnings, price trends, and broader institutional activity to provide clearer direction.On the financial front, Shilpa Medicare reported revenues of ₹409.7 crore in Q3 FY26 vs ₹3,19.3 crore a year ago. The net profits jumped to ₹44.9 crore vs ₹314 crore.Shilpa Medicare has been rapidly expanding.
In February 2026, the company announced an expansion into the Latin American market.SteinCares, a speciality healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd, a subsidiary of Shilpa Medicare, announced a strategic licensing agreement to commercialize a biosimilar across Latin America.Further, Shipla Medicare is planning to build a large-scale peptide manufacturing capacity, for which, the work has already started, and
. Read on livemint.com